Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) will be able to conduct phase I clinical trials for HLX43 for injection after obtaining approval from the US Food and Drug Administration, according to a Shanghai bourse filing on Friday.
The drug will be tested as a treatment for thymic carcinoma.
The Chinese pharmaceutical company also plans to conduct global multicenter clinical studies on the drug for this condition in other countries, such as Japan and Australia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.